AIM

AIM

AMEX

AIM ImmunoTech Inc.

1.03

0.32(45.07%)
Volume

181.8M

Market Cap

$3.51M

P/E Ratio

-1.68

EPS

$-11.21


Price Chart

Price Alerts

No price alerts set. Add an alert to get notified!

Notify when price goes above $120.00
Notify when price goes above $180.00
Notify when price goes below $180.00

Key Financial Ratios

P/E Ratio

-1.68

P/B Ratio

-21.99

EPS

$-11.21

ROE

1,310.14%

Profit Margin

-10,188.24%

Operating Margin

-11,630.59%

Peer Comparison

Compare TSM with similar companies in the sector

Company Price Change % P/E Market Cap D/E
CANF
Can-Fite BioPharma Ltd.
$3.37 -1.75% -674.87 $2.90M 0.02
ENSC
Ensysce Biosciences, Inc.
$0.62 29.92% -0.16 $1.46M 0.30
KALA
KALA BIO, Inc.
$0.25 -0.83% -0.05 $5.46M -3.58
KTTA
Pasithea Therapeutics Corp.
$0.84 -2.20% -0.46 $6.24M 0.00
OGEN
Oragenics, Inc.
$0.76 -2.47% 0.00 $3.19M 0.03
QNRX
Quoin Pharmaceuticals, Ltd.
$7.84 -3.69% -0.33 $4.60M 0.00
SNGX
Soligenix, Inc.
$1.21 -3.97% -0.46 $12.25M 0.05
TCRT
Alaunos Therapeutics, Inc.
$3.31 6.09% -1.80 $7.43M 0.00
VYNE
VYNE Therapeutics Inc.
$0.59 -4.13% -0.94 $9.78M 0.00
XTLB
XTL Biopharmaceuticals Ltd.
$0.60 -2.22% -5.62 $817,415 0.03

* Peer stocks are selected based on market capitalization and sector

Private Notes

Key Statistics

52 Week High

$34.92

52 Week Low

$0.61

Dividend

$0.00

Dividend Yield

0.00%

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.